Filing Details
- Accession Number:
- 0001209191-23-024388
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-14 19:20:38
- Reporting Period:
- 2023-04-12
- Accepted Time:
- 2023-04-14 19:20:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 25743 | Therapeuticsmd Inc. | TXMD | Pharmaceutical Preparations (2834) | 870233535 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1820187 | D Marlan Walker | 951 Yamato Road Suite 220 Boca Raton FL 33431 | Chief Executive Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-04-12 | 3,030 | $0.00 | 8,999 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-04-12 | 1,010 | $0.00 | 10,009 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-04-12 | 1,734 | $0.00 | 11,743 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-04-12 | 1,734 | $0.00 | 13,477 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-12 | 1,170 | $3.65 | 12,307 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Stock Units | Disposition | 2023-04-12 | 3,030 | $0.00 | 3,030 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-04-12 | 1,010 | $0.00 | 1,010 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-04-12 | 1,734 | $0.00 | 1,734 | $0.00 |
| Common Stock | Performance Stock Units | Disposition | 2023-04-12 | 1,734 | $0.00 | 1,734 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct | ||
| 0 | No | 4 | M | Direct | ||
| 3,466 | No | 4 | M | Direct | ||
| 3,466 | No | 4 | M | Direct |
Footnotes
- The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer.
- Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023.
- Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.
- The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023. One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021. Each PSU represents a contingent right to receive one share of common stock of the issuer.
Billionaire Hedge Funds
